- ROUNDTABLE: Pharmacy’s future in sync with technology
- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
BASKING RIDGE, N.J. — Mylan Specialty announced Thursday the introduction of a "$0 Co-Pay Offer" on a product used to treat severe allergic reactions.
The drug maker is offering a co-pay card to patients with or without insurance for the EpiPen in recognition of the 25th anniversary of its approval by the Food and Drug Administration. The co-pay card is available online at EpiPen.com, and the offer will expire on Dec. 31.
"Mylan has a long-standing dedication to increase access to epinephrine auto-injectors through innovative access solutions such as the EpiPen4Schools program, and we're pleased to continue that commitment by introducing our $0 Co-Pay Offer," Mylan CEO Heather Bresch said.